<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078949</url>
  </required_header>
  <id_info>
    <org_study_id>LY12</org_study_id>
    <secondary_id>CAN-NCIC-LY12</secondary_id>
    <secondary_id>CDR0000353203</secondary_id>
    <nct_id>NCT00078949</nct_id>
    <nct_alias>NCT00089817</nct_alias>
  </id_info>
  <brief_title>Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and
      cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or
      die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to
      give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies,
      such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing
      substances to them without harming normal cells. Giving rituximab as maintenance therapy
      after stem cell transplantation may kill any remaining cancer cells. It is not yet known
      which salvage chemotherapy regimen is more effective before autologous stem cell
      transplantation in treating relapsed or refractory non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying salvage chemotherapy using
      dexamethasone, cisplatin, and gemcitabine to see how well it works compared to dexamethasone,
      cisplatin, and cytarabine given before autologous stem cell transplantation in treating
      patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. This trial also is
      studying giving rituximab as maintenance therapy to see how well it works compared to no
      further therapy after stem cell transplantation. Rituximab was added to both salvage
      treatment arms for CD20+ patients in a protocol amendment in 2005.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Salvage therapy

      Primary

        -  Compare the response rate and transplantation rate in patients with relapsed or
           refractory aggressive non-Hodgkin's lymphoma when treated with salvage chemotherapy
           comprising dexamethasone, cisplatin, and gemcitabine with or without rituximab vs a
           standard platinum-based regimen (dexamethasone, cisplatin, and high-dose cytarabine with
           or without rituximab).

        -  To compare the transplantation rates of the two protocol salvage regimens.

      Secondary

        -  Compare the event-free and overall survival of patients treated with these regimens.

        -  Compare the success rate of these regimens, in terms of getting patients to autologous
           stem cell transplantation and successful mobilization after high-dose chemotherapy.

        -  Compare the quality of life of patients treated with these salvage regimens.

        -  Compare the toxic effects of these salvage regimens in these patients.

        -  Compare resource utilization for patients treated with these salvage regimens.

        -  Compare relative medical and societal costs of these salvage regimens with outcomes in
           these patients.

      Maintenance therapy

      Primary

        -  Compare the 2-year event-free survival of patients with CD20+ B-cell lymphoma treated
           with maintenance rituximab after these salvage regimens and autologous stem cell
           transplantation to those patients who received no further treatment.

      Secondary

        -  Compare the 2-year survival of patients treated with or without maintenance rituximab.

        -  Compare the toxic effects of rituximab vs observation alone in these patients.

      OUTLINE: This is a randomized, multicenter study. For salvage therapy, patients are
      stratified according to participating center, International Prognostic Index score at
      relapse/study entry (0 or 1 vs 2 vs ≥ 3), immunophenotype (B cell vs T cell), response to or
      response duration after initial chemotherapy (no response or progressive disease vs &gt; 1 year
      vs ≤ 1 year), and prior rituximab (yes vs no). For maintenance therapy, patients are
      stratified according to participating center, salvage therapy treatment randomization (with
      or without rituximab, cisplatin, dexamethasone, and gemcitabine vs with or without rituximab,
      cisplatin, dexamethasone, and cytarabine), response to salvage therapy (complete response
      [CR] and CR unconfirmed [CRu] vs partial response [PR] vs stable disease [SD]), and prior
      rituximab (yes vs no).

        -  Salvage therapy: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or
                orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8. Patients
                with CD20+ B cell lymphoma receive rituximab IV over 1.5-6 hours on day 1.

             -  Arm II: Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in
                arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day
                2. Patients with CD20+ B cell lymphoma receive rituximab IV over 1.5-6 hours on day
                1.

      In both arms, treatment repeats every 21 days for at least 2 courses in the absence of
      disease progression or unacceptable toxicity.

      Patients are reassessed after 2 courses. Patients with progressive disease are removed from
      study. Patients with a CR, CRu, or PR proceed to autologous stem cell transplantation (ASCT).
      Patients with SD may proceed to ASCT or receive 1 additional course of salvage therapy at the
      discretion of the investigator. Patients receiving an additional course of salvage therapy
      are then reassessed after the completion of therapy. Patients with progressive disease are
      removed from study. Patients with a PR proceed to ASCT. Patients with SD may proceed to ASCT
      or be followed off study at the discretion of the investigator.

        -  ASCT: Responding patients (or those with stable disease, if that is the center's
           policy)undergo mobilization, stem cell harvest, and subsequent ASCT. Patients with CD20+
           B-cell disease are randomized to maintenance therapy or observation.

        -  Maintenance therapy: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Beginning on day 28 posttransplantation, patients receive rituximab IV once
                every 2 months for 6 doses (a total of 12 months) in the absence of disease
                progression or unacceptable toxicity.

             -  Arm II: Patients undergo observation only. Quality of life is assessed at baseline,
                days 1 and 10 of course 2, day 1 of course 3 (if given), on the last day of salvage
                therapy (or the first day of mobilization, if given), and at 1 month
                posttransplantation.

      Patients who undergo ASCT are followed at months 1, 3, 7, 13, 19, and 25 and then annually
      thereafter. Patients who complete salvage therapy, but do not undergo ASCT are followed at
      months 4, 8, 14, 20, and 26 and then annually thereafter. Patients who relapse or progress
      are followed every 6 months until 25 months from ASCT or 26 months from completion of salvage
      therapy and then annually thereafter.

      PROJECTED ACCRUAL: A total of 637 patients will be accrued for this study within 3-4 years
      for the first randomization, and 240 transplanted CD20+ patients will be needed for the
      second randomization.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate of Patients After 2 Courses of Chemotherapy</measure>
    <time_frame>After 2 cycle of treatment</time_frame>
    <description>The overall response rate by arm is calculated as total number of responders (CR + CRu + PR) / (all patients in the ITT analysis population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplantation Rate of Patients After 2 Courses of Chemotherapy</measure>
    <time_frame>During period 1 (salvage chemotherapy)</time_frame>
    <description>Transplantation rate is defined as the number of patients who respond sufficiently to protocol salvage chemotherapy to be planned for transplantation minus those who do not meet the endpoint of successful transplantation, divided by the number of all randomized patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival of Patients on Maintenance Randomization (Period 2)</measure>
    <time_frame>during the period 2 (up to10 years)</time_frame>
    <description>Number of patients who develop EFS event during maintenance randomization (period 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mobilization Rate of Patients on Treatment Arm I Assessed by CD34 Count After 2 Courses of Therapy and Stem Cell Harvesting</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Assessed by NCI CTC v2.0 for 2 Years in Patients on Treatment Arm II</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">619</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Salvage arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance arm II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo observation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Maintenance arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Salvage arm I</arm_group_label>
    <arm_group_label>Salvage arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Salvage arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Salvage arm I</arm_group_label>
    <arm_group_label>Salvage arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Salvage arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following
             subtypes:

               -  Diffuse large cell lymphoma (includes primary mediastinal B-cell lymphoma and
                  T-cell-rich B-cell lymphoma)

               -  Prior indolent lymphoma (e.g., follicular center cell lymphoma; marginal zone
                  lymphoma, including extranodal mucosa-associated lymphoid tissue [MALT] lymphoma;
                  and lymphoplasmacytoid lymphoma) with transformation to diffuse large B-cell
                  lymphoma at relapse

                    -  Must be histologically confirmed

                    -  No transformed lymphoma at diagnosis with subsequent indolent histology
                       without transformation at relapse

               -  Peripheral T-cell lymphoma

               -  Anaplastic large cell lymphoma

               -  Small noncleaved Burkitt-like lymphoma

          -  T-cell or B-cell lineage confirmed by immunohistochemistry

          -  Clinically or radiologically documented disease meeting either of the following
             criteria:

               -  Measurable disease, defined as at least 1 bidimensionally measurable site of
                  disease using clinical exam, CT scan, or MRI

                    -  Lymph nodes must be &gt; 1.5 cm by physical exam or CT scan

                    -  Other non-nodal lesions must be ≥ 1.0 cm by physical exam, CT scan, or MRI

                    -  Bone lesions are not considered measurable

               -  Evaluable disease, defined as only nonmeasurable disease, including any of the
                  following:

                    -  Marrow infiltration

                    -  Cytology-confirmed ascites or effusions

                    -  Bony involvement

                    -  Enlarged liver or spleen

                    -  Unidimensionally measurable intrathoracic or abdominal masses

          -  Previously treated with 1, and only 1, chemotherapy regimen including an anthracycline
             and excluding cisplatin, cytarabine, and gemcitabine

          -  No uncontrolled CNS involvement by lymphoma

               -  No CNS disease at time of relapse

               -  CNS disease diagnosed at initial presentation allowed provided a complete
                  response for CNS disease was achieved and maintained

        PATIENT CHARACTERISTICS:

        Age

          -  16 to 65

        Performance status

          -  ECOG 0-3

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute granulocyte count ≥ 1,000/mm^3

          -  Platelet count ≥ 75,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST or ALT ≤ 2.5 times ULN (5 times ULN if liver involvement with lymphoma)

          -  Hepatitis B status known (for patients with a history of hepatitis B or who are at
             high risk of hepatitis B infection)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No significant cardiac dysfunction or cardiovascular disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Willing to complete quality of life questionnaires

          -  HIV negative

          -  No active, uncontrolled bacterial, fungal, or viral infection

          -  No other malignancy within the past 5 years except adequately treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No other concurrent serious illness or medical condition that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Chemotherapy

          -  Prior rituximab allowed

        Chemotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior IV chemotherapy

          -  No prior high-dose chemotherapy with stem cell transplantation

        Endocrine therapy

          -  No concurrent corticosteroids except for physiologic replacement

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy and recovered

               -  Exceptions may be made for low-dose, non-myelosuppressive radiotherapy

          -  No prior radiotherapy to more than 25% of functioning bone marrow

          -  Involved-field radiotherapy may be given to areas of bulky disease at relapse (≥ 5 cm)
             after stem cell transplantation, according to the center's policy

        Surgery

          -  At least 2 weeks since prior major surgery

        Other

          -  No other concurrent anticancer therapy

          -  No other concurrent experimental agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. Crump, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Federico, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Modena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush-Presbyterian-St. Luke's Medical Centre</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Barrett Cancer Centre</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <results_reference>
    <citation>Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.</citation>
    <PMID>25267740</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <results_first_submitted>September 17, 2014</results_first_submitted>
  <results_first_submitted_qc>October 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2014</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only a selected subset of patient (N = 230) were randomized in period 2 of this study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Salvage GDP</title>
          <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
cisplatin: Given IV
dexamethasone: Given IV
gemcitabine hydrochloride: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Salvage DHAP</title>
          <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
cisplatin: Given IV
cytarabine: Given IV
dexamethasone: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Maintenance</title>
          <description>Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV</description>
        </group>
        <group group_id="P4">
          <title>Observation</title>
          <description>Patients undergo observation only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Salvage</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="304"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="115"/>
                <participants group_id="P4" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Salvage GDP</title>
          <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
cisplatin: Given IV
dexamethasone: Given IV
gemcitabine hydrochloride: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Salvage DHAP</title>
          <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
cisplatin: Given IV
cytarabine: Given IV
dexamethasone: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Maintenance</title>
          <description>Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV</description>
        </group>
        <group group_id="B4">
          <title>Observation</title>
          <description>Patients undergo observation only.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="310"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="619"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="19" upper_limit="71"/>
                    <measurement group_id="B2" value="55" lower_limit="23" upper_limit="74"/>
                    <measurement group_id="B5" value="55" lower_limit="19" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B5" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate of Patients After 2 Courses of Chemotherapy</title>
        <description>The overall response rate by arm is calculated as total number of responders (CR + CRu + PR) / (all patients in the ITT analysis population).</description>
        <time_frame>After 2 cycle of treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Salvage GDP</title>
            <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
cisplatin: Given IV
dexamethasone: Given IV
gemcitabine hydrochloride: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Salvage DHAP</title>
            <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
cisplatin: Given IV
cytarabine: Given IV
dexamethasone: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate of Patients After 2 Courses of Chemotherapy</title>
          <description>The overall response rate by arm is calculated as total number of responders (CR + CRu + PR) / (all patients in the ITT analysis population).</description>
          <population>ITT population</population>
          <units>percentage of response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The literature has suggested that the ORR is approximately 50% for this patient population treated with DHAP. The treatment difference is defined as the response rate for the DHAP arm minus that of GDP arm. We would consider GDP to be non-inferior to DHAP if we are 95% sure that the true difference is less than 10%. In order to rule out that the 10% difference with 80% power, we need to accrue a total of 630 eligible patients. The actual sample size for this final analysis is 619 patients.</non_inferiority_desc>
            <p_value>0.005</p_value>
            <p_value_desc>p-value for non-inferiority</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Transplantation Rate of Patients After 2 Courses of Chemotherapy</title>
        <description>Transplantation rate is defined as the number of patients who respond sufficiently to protocol salvage chemotherapy to be planned for transplantation minus those who do not meet the endpoint of successful transplantation, divided by the number of all randomized patients</description>
        <time_frame>During period 1 (salvage chemotherapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salvage GDP</title>
            <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
cisplatin: Given IV
dexamethasone: Given IV
gemcitabine hydrochloride: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Salvage DHAP</title>
            <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
cisplatin: Given IV
cytarabine: Given IV
dexamethasone: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Transplantation Rate of Patients After 2 Courses of Chemotherapy</title>
          <description>Transplantation rate is defined as the number of patients who respond sufficiently to protocol salvage chemotherapy to be planned for transplantation minus those who do not meet the endpoint of successful transplantation, divided by the number of all randomized patients</description>
          <units>percentage of transplantation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival of Patients on Maintenance Randomization (Period 2)</title>
        <description>Number of patients who develop EFS event during maintenance randomization (period 2)</description>
        <time_frame>during the period 2 (up to10 years)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance</title>
            <description>Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Patients undergo observation only.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival of Patients on Maintenance Randomization (Period 2)</title>
          <description>Number of patients who develop EFS event during maintenance randomization (period 2)</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was estimated that 240 patients will be eligible for the maintenance question, and randomized with a 1:1 ratio to either rituximab or observation. It is expected that the 2-year event-free survival will be 50% on the observation arm. In order to detect a 15% difference in the 2-year event-free survival with an 80% power using a two-sided 5% level test, 142 events are required to detect an HR of 0.622.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mobilization Rate of Patients on Treatment Arm I Assessed by CD34 Count After 2 Courses of Therapy and Stem Cell Harvesting</title>
        <time_frame>10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Assessed by NCI CTC v2.0 for 2 Years in Patients on Treatment Arm II</title>
        <time_frame>10 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8.5 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Salvage GDP</title>
          <description>Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
cisplatin: Given IV
dexamethasone: Given IV
gemcitabine hydrochloride: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Salvage DHAP</title>
          <description>Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
cisplatin: Given IV
cytarabine: Given IV
dexamethasone: Given IV</description>
        </group>
        <group group_id="E3">
          <title>Maintenance</title>
          <description>Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV</description>
        </group>
        <group group_id="E4">
          <title>Observation</title>
          <description>Patients undergo observation only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Melena/GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear/hearing</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/o neutropen</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seninor Biostatistician for LY12</name_or_title>
      <organization>NCIC</organization>
      <phone>613-533-6000 ext 77703</phone>
      <email>bechen@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

